A Recombinant Sialidase Fusion Protein Effectively Inhibits Human Parainfluenza Viral Infection in Vitro and in Vivo

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2010 Jun 11

PMID 20533871

Citations 49

Authors

Anne Moscona

Matteo Porotto

Samantha Palmer

Caroline Tai

Lori Aschenbrenner

Gallen Triana-Baltzer

Qi-Xiang Li

David Wurtman

Stefan Niewiesk

Fang Fang

Affiliations

Soon will be listed here.

Abstract

Background: The first step in infection by human parainfluenza viruses (HPIVs) is binding to the surface of respiratory epithelial cells via interaction between viral receptor-binding molecules and sialic acid-containing receptors. DAS181, a recombinant sialidase protein containing the catalytic domain of Actinomyces viscosus sialidase, removes cell surface sialic acid, and we proposed that it would inhibit HPIV infection.

Methods: Depletion of sialic acid receptors by DAS181 was evaluated by lectin-binding assays. Anti-HPIV activity in cultured cell lines and in human airway epithelium was assessed by the reduction in viral genomes and/or plaque forming units on treatment. In vivo efficacy of intranasally administered DAS181 was assessed using a cotton rat model.

Results: DAS181-mediated desialylation led to anti-HPIV activity in cell lines and human airway epithelium. Intranasal DAS181 in cotton rats, a model for human disease, significantly curtailed infection.

Conclusions: Enzymatic removal of the sialic acid moiety of HPIV receptors inhibits infection with all tested HPIV strains, both in vitro and in cotton rats. Enzyme-mediated removal of sialic acid receptors represents a novel antiviral strategy for HPIV. The results of this study raise the possibility of a broad spectrum antiviral agent for influenza virus and HPIVs.

Citing Articles

Intranasally administrated fusion-inhibitory lipopeptides block SARS-CoV-2 infection in mice and enable long-term protective immunity.

Mougari S, Favede V, Predella C, Reynard O, Durand S, Mazelier M Commun Biol. 2025; 8(1):57.

PMID: 39814955 PMC: 11735783. DOI: 10.1038/s42003-025-07491-4.

Interplay of Modified Sialic Acid Inhibitors and the Human Parainfluenza Virus 1 Hemagglutinin-Neuraminidase Active Site.

Rota P, La Rocca P, Bonfante F, Pagliari M, Cirillo F, Piccoli M ACS Med Chem Lett. 2023; 14(10):1383-1388.

PMID: 37849540 PMC: 10577888. DOI: 10.1021/acsmedchemlett.3c00291.

Broad-spectrum Respiratory Virus Entry Inhibitors.

Zhao H, Yuen K Adv Exp Med Biol. 2022; 1366:137-153.

PMID: 35412139 DOI: 10.1007/978-981-16-8702-0_9.

Parainfluenza virus entry at the onset of infection.

Marcink T, Porotto M, Moscona A Adv Virus Res. 2021; 111:1-29.

PMID: 34663496 PMC: 10270304. DOI: 10.1016/bs.aivir.2021.07.001.

Human parainfluenza virus evolution during lung infection of immunocompromised individuals promotes viral persistence.

Greninger A, Rybkina K, Lin M, Drew-Bear J, Marcink T, Shean R J Clin Invest. 2021; 131(23).

PMID: 34609969 PMC: 8631596. DOI: 10.1172/JCI150506.

References

Suzuki T, Portner A, Scroggs R, Uchikawa M, Koyama N, Matsuo K . Receptor specificities of human respiroviruses. J Virol. 2001; 75(10):4604-13. PMC: 114213. DOI: 10.1128/JVI.75.10.4604-4613.2001. View

Moscona A . Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease. J Clin Invest. 2005; 115(7):1688-98. PMC: 1159152. DOI: 10.1172/JCI25669. View

Zhang L, Bukreyev A, Thompson C, Watson B, Peeples M, Collins P . Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J Virol. 2004; 79(2):1113-24. PMC: 538579. DOI: 10.1128/JVI.79.2.1113-1124.2005. View

Murrell M, Porotto M, Weber T, Greengard O, Moscona A . Mutations in human parainfluenza virus type 3 hemagglutinin-neuraminidase causing increased receptor binding activity and resistance to the transition state sialic acid analog 4-GU-DANA (Zanamivir). J Virol. 2002; 77(1):309-17. PMC: 140643. DOI: 10.1128/jvi.77.1.309-317.2003. View

Hall C . Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001; 344(25):1917-28. DOI: 10.1056/NEJM200106213442507. View

PORTER D, Prince G, Hemming V, PORTER H . Pathogenesis of human parainfluenza virus 3 infection in two species of cotton rats: Sigmodon hispidus develops bronchiolitis, while Sigmodon fulviventer develops interstitial pneumonia. J Virol. 1991; 65(1):103-11. PMC: 240494. DOI: 10.1128/JVI.65.1.103-111.1991. View

Prince G, Ottolini M, Moscona A . Contribution of the human parainfluenza virus type 3 HN-receptor interaction to pathogenesis in vivo. J Virol. 2001; 75(24):12446-51. PMC: 116141. DOI: 10.1128/JVI.75.24.12446-12451.2001. View

Loughlin G, Moscona A . The cell biology of acute childhood respiratory disease: therapeutic implications. Pediatr Clin North Am. 2006; 53(5):929-59, ix-x. PMC: 7111702. DOI: 10.1016/j.pcl.2006.08.004. View

Roth J, Li J, Smee D, Morrey J, Barnard D . A recombinant, infectious human parainfluenza virus type 3 expressing the enhanced green fluorescent protein for use in high-throughput antiviral assays. Antiviral Res. 2009; 82(1):12-21. PMC: 2701465. DOI: 10.1016/j.antiviral.2009.01.001. View

10.

Madhi S, Cutland C, Zhu Y, Hackell J, Newman F, Blackburn N . Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers. Vaccine. 2006; 24(13):2432-9. DOI: 10.1016/j.vaccine.2005.12.002. View

11.

Amonsen M, Smith D, Cummings R, Air G . Human parainfluenza viruses hPIV1 and hPIV3 bind oligosaccharides with alpha2-3-linked sialic acids that are distinct from those bound by H5 avian influenza virus hemagglutinin. J Virol. 2007; 81(15):8341-5. PMC: 1951310. DOI: 10.1128/JVI.00718-07. View

12.

Holmgren J, Svennerholm L, Elwing H, Fredman P, Strannegard O . Sendai virus receptor: proposed recognition structure based on binding to plastic-adsorbed gangliosides. Proc Natl Acad Sci U S A. 1980; 77(4):1947-50. PMC: 348626. DOI: 10.1073/pnas.77.4.1947. View

13.

Levin Perlman S, Jordan M, BROSSMER R, Greengard O, Moscona A . The use of a quantitative fusion assay to evaluate HN-receptor interaction for human parainfluenza virus type 3. Virology. 1999; 265(1):57-65. DOI: 10.1006/viro.1999.0024. View

14.

Moscona A . Neuraminidase inhibitors for influenza. N Engl J Med. 2005; 353(13):1363-73. DOI: 10.1056/NEJMra050740. View

15.

Malakhov M, Aschenbrenner L, Smee D, Wandersee M, Sidwell R, Gubareva L . Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother. 2006; 50(4):1470-9. PMC: 1426979. DOI: 10.1128/AAC.50.4.1470-1479.2006. View

16.

Zhang L, Peeples M, Boucher R, Collins P, Pickles R . Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol. 2002; 76(11):5654-66. PMC: 137037. DOI: 10.1128/jvi.76.11.5654-5666.2002. View

17.

Schauer R . Chemistry, metabolism, and biological functions of sialic acids. Adv Carbohydr Chem Biochem. 1982; 40:131-234. DOI: 10.1016/s0065-2318(08)60109-2. View

18.

Nicholls J, Chan R, Russell R, Air G, Peiris J . Evolving complexities of influenza virus and its receptors. Trends Microbiol. 2008; 16(4):149-57. DOI: 10.1016/j.tim.2008.01.008. View

19.

Porotto M, Fornabaio M, Greengard O, Murrell M, Kellogg G, Moscona A . Paramyxovirus receptor-binding molecules: engagement of one site on the hemagglutinin-neuraminidase protein modulates activity at the second site. J Virol. 2006; 80(3):1204-13. PMC: 1346948. DOI: 10.1128/JVI.80.3.1204-1213.2006. View

20.

Moscona A, Peluso R . Fusion properties of cells infected with human parainfluenza virus type 3: receptor requirements for viral spread and virus-mediated membrane fusion. J Virol. 1992; 66(11):6280-7. PMC: 240119. DOI: 10.1128/JVI.66.11.6280-6287.1992. View